Navigation Links
Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO)
Date:4/20/2011

an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this statement related to our product candidates is preliminary and investigative and is not part of the labeling approved by the U.S. FDA or the European Medicines Agency (EMA) for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA, EMA or other applicable regulatory bodies can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the approved labeling for the products, and not the information discussed in this statement.

CONTACT: Amgen, Thousand Oaks
Christine Regan: +1 (805) 447-5476 (Media)
Arvind Sood: +1 (805) 447-1060 (Investors)

CONTACT: UCB, Brussels
Antje Witte, Investor Relations UCB
T +32.2.559.9414, antje.witte@ucb.com
Michael Tuck-Sherman, Investor Relations, UCB
T +32.2.559.9712, michael.tuck-sherman@ucb.com
Nancy Nackaerts, External Communications, UCB
M: +32 473 86 44 14, nancy.nackaerts@ucb.com
Scott Fleming, Global Communications Manager UCB– Immunology
T +44.770.277.7378, Scott.fleming@ucb.com

(Logo:  http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

(Logo:  http://photos.prnewswire.com/prnh/20110421/LA87263LOGO)


'/>"/>
SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amgen’s First Quarter 2011 Revenue Increased 3 Percent to $3.7 Billion
2. Amgen to Webcast 2011 Business Review Meeting on April 21
3. Amgen Announces Webcast of 2011 First Quarter Financial Results
4. Amgen Establishes Commercial Operations in Brazil
5. Amgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe
6. Amgen Donates $1 Million to Help Japanese Disaster Victims
7. Amgen Completes Acquisition of BioVex
8. NBPTS and Amgen Foundation Join to Bolster Science Education
9. Amgen to Present at the Citi 2011 Global Healthcare Conference
10. CURE Magazine Teams Up With Amgen Oncology and Breakaway from Cancer® to Launch 2011 Extraordinary Healer Award for Oncology Nursing
11. Boehringer Ingelheim to Purchase Amgens Fremont (USA) Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... PHOENIX , Aug. 20, 2014 ... cutting-edge next-generation sequencing and proteomic diagnostics and biomarker ... a collaboration with TESARO, Inc.  Paradigm will use ... samples from clinical trials to better predict which ... TSR-011.  This may lead to more successful clinical trial ...
(Date:8/20/2014)... Aug. 20, 2014 Reportlinker.com announces that ... its catalogue: The Market for Medical ... The European, Middle Eastern and African markets ... As part of its coverage, this study: The ... the EMEA medical device markets and estimates markets ...
(Date:8/20/2014)... Texas , Aug. 20, 2014  Quantum ... five diverse sets of patent families from Bayer Technology ... innovation driver for Bayer AG of Leverkusen, ... patents acquired provide broad intellectual property protection for ... economical high-volume quantum dot (QD) manufacturing. In addition, ...
Breaking Medicine Technology:Paradigm Announces Molecular Profiling Collaboration with TESARO, Inc. 2The Market for Medical Devices in EMEA 2The Market for Medical Devices in EMEA 3The Market for Medical Devices in EMEA 4The Market for Medical Devices in EMEA 5Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 2Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 4
... DIEGO, Feb. 3, 2011 Ceregene, Inc., a biopharmaceutical ... and dosing in its CERE-120 (AAV2-neurturin) Phase 2b multi-center, ... was initiated in October 2010 and all 11 centers ...  These sites are among the best movement disorders centers ...
... 3, 2011 Corium International, Inc., a privately-held ... appointment of Dr. Bhaskar Chaudhuri and David L. ... most recently served as President of Valeant Pharmaceuticals ... Officer of Dow Pharmaceutical Services, Inc.  Mr. Greenwood ...
Cached Medicine Technology:Ceregene Advances Phase 2b CERE-120 (AAV2-neurturin) Trial in Parkinson's Disease 2Ceregene Advances Phase 2b CERE-120 (AAV2-neurturin) Trial in Parkinson's Disease 3Ceregene Advances Phase 2b CERE-120 (AAV2-neurturin) Trial in Parkinson's Disease 4Ceregene Advances Phase 2b CERE-120 (AAV2-neurturin) Trial in Parkinson's Disease 5Corium International Adds Dr. Bhaskar Chaudhuri and David Greenwood to Board of Directors 2Corium International Adds Dr. Bhaskar Chaudhuri and David Greenwood to Board of Directors 3
(Date:8/20/2014)... York, New York (PRWEB) August 20, 2014 ... with the use of power morcellators ( http://www.injurybeacon.com/power-morcellator/ ) ... LLP notes that two U.S. Senators from New York ... to seek a recall of the devices. In a ... Schumer, both Democrats, also implored the agency to seriously ...
(Date:8/20/2014)... contrast to evidence that the amygdala stimulates stress ... Research Center, Emory University have found that the ... during the early development of nonhuman primates. , ... Journal of Neuroscience . , The amygdala is ... important for responses to threatening situations and learning ...
(Date:8/20/2014)... Reinberg HealthDay Reporter TUESDAY, ... that dismantles a baby,s immune system is twice as common ... million infants says. This is the first evaluation of ... condition known as severe combined immunodeficiency (SCID), or "Bubble Boy" ... this condition by the boy in the bubble, who was ...
(Date:8/20/2014)... Santa Rosa, CA (PRWEB) August 20, 2014 ... is the 12 per diode panel band perfect spectrum that ... plants are most likely to use during photosynthesis. A ... spectral bands is that they almost exclusively reside between 440-480 ... 620-680 on the red side of the spectrum. The KIND ...
(Date:8/20/2014)... 2014 Braverman Eye Center is now ... their experienced surgeons trained in PresbyLasik. The Braverman Eye ... lost or inaccurate vision. Their diligent service and adoption ... making it possible for Presbyopia patients to have better ... in people in the age group of 40 to ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 4Health News:Maturing brain flips function of amygdala in regulating stress hormones 2Health News:Maturing brain flips function of amygdala in regulating stress hormones 3Health News:'Bubble Boy' Disease May Be More Common Than Thought 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 3Health News:Cheap LED Grow Lights Are Quickly Being Replaced by Premium Grow Lights 2Health News:Braverman Eye Center Now Offers Multifocal PresbyLasik in Florida by Trained Surgeons 2
... for young people do not always provide the same quality ... As our population ages and requires more healthcare, hospitals need ... over 65s and implement programs to meet their distinct needs, ... St. Michael,s Hospital. The study, published in the June ...
... (HealthDay News) -- People who seek treatment in an emergency ... likely to be readmitted to the hospital as those who ... The finding suggests that emergency departments can help reduce the ... were to present the study Friday at the Society for ...
... Reinberg HealthDay Reporter , THURSDAY, June 2 ... Americans to eat healthier meals and fight the obesity ... icon called MyPlate. MyPlate replaces the U.S. Department ... but had become too complicated in ensuing years, many ...
... conserving therapy for women 70 years and older with ... opting for radioactive implants and those with estrogen positive ... an abstract being presented at the American Society of ... University Hospital researchers on Saturday, June 4. The ...
... are one step closer to helping millions of people ... or damage from treatment of diseases. The ... Oral Health and Rehabilitation, UofL School of Dentistry, and ... the salivary gland. The National Institutes of Health supported ...
... 2 (HealthDay News) -- Obesity and insulin resistance constitute a ... according to a new study that found drinking modest amounts ... condition. For their study, published online May 23 in ... people to either abstain from alcohol or drink one (women) ...
Cached Medicine News:Health News:Not all hospitals treat elderly the same 2Health News:Emergency Care May Be Key to Hospital Readmissions 2Health News:U.S. Serves Up New Nutrition Guidelines on 'MyPlate' 2Health News:U.S. Serves Up New Nutrition Guidelines on 'MyPlate' 3Health News:ASCO: Emerging trends in radiation therapy for women over 70 with early stage breast cancer 2Health News:UofL researchers uncover mechanism in saliva production 2Health News:Obesity Greater Risk for Fatty Liver Than Alcohol, Study Finds 2
... Stainless steel workbench top ... is adjustable from 25"-34". Available ... configurations. Accessories include shelves, drawers, ... Terra is an expert in ...
... metal frames ensure cleanroom ... cleanliness and chemical resistance. ... with user-friendly pnuematic controls ... Fixed footring standard. Five ...
... ideal modular cleanroom for biological safety ... require cleanliness (to Class 10/ISO 3) ... to create ultra-smooth surfaces that are ... One-inch radius corners simplify cleaning. Unique ...
Inquire...
Medicine Products: